Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice

Summary

The pharmacokinetics of VP16 have been investigated in Lewis lung bearing mice after i.v. doses of 13 and 40 mg/kg. At both doses the plasma elimination half-life was around 30 min. The lowest VP16-213 levels were in brain and primary tumor. Drug concentrations were much higher in metastases than in primary tumor. The highest concentrations were in small intestine, liver and kidney. Drug levels in the liver were disproportionally higher after 40 mg/kg, the AUC value being approximately 12 times greater than after 13 mg/kg. Urinary excretion of VP16-213 as unchanged drug accounted for 20–30% of the administered dose in the 60 h after treatment. The concentration cytotoxicity curve was very steep and apparently similar for cells derived from primary tumor or metastases grown in vitro.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Allen LM, Creaven PJ (1975) Comparison of human pharmacokinetics of VM26 and VP16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697

  2. 2.

    Cattan A, Pourny C, Carpentier Y, Cattan E, Barouh M (1976) Antimetastasis effect of two derivatives of epipodophyllotoxin in mice. Eur J Cancer 12:797

  3. 3.

    D'Incalci M, Farina P, Fasoli M, Marsoni S (1981) VP16 plasma levels after i.v. and two methods of oral administration to choriocarcinoma patients. Proc Am Soc Clin Oncol 22:357

  4. 4.

    Donelli MG, Colombo T, Broggini M, Garattini S (1977) Differential distribution of antitumoral agents in primary and secondary tumors. Cancer Treat Rep 61:1319

  5. 5.

    Farina P, Marzillo G, D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethylepi-podophyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (VP16-213) human plasma. J Chromatogr 222:141

  6. 6.

    Issell BF, Crooke ST (1979) Etoposide (VP16-213). Cancer Treat Rev 6:107

  7. 7.

    Nissen NI, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new antitumor agent, 4′-demethylepipodo-phyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (NSC-141540; VP16-213). Cancer Chemother Rep 56:769

  8. 8.

    Rivera G, Avery T, Pratt C (1975) 4′-Demethylepipodophyllotoxin-9-(4,6-o-2-thenylidene-β-d-glucopyranoside) (NSC-122819; VM26) and 4′-demethylepipodophyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (NSC-141540; VP16-213) in childhood cancer: Preliminary observations. Cancer Chemother Rep 59:743

  9. 9.

    Rozencweig M, Van Hoff DD, Henney JE, Muggia FM (1977) VM26 and VP16-213: A comparative analysis. Cancer 40:334

  10. 10.

    Stähelin H (1973) Activity of a new glycosidic lignan derivative (VP16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 9:215

Download references

Author information

Correspondence to Maurizio D'Incalci.

Additional information

This work was partially supported by CNR Progetto Finalizzato No. 80.01593.96. The generous contribution of the Italian Association for Cancer Research, Milan, Italy, is gratefully acknowledged.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Colombo, T., Broggini, M., Torti, L. et al. Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemother. Pharmacol. 7, 127–131 (1982). https://doi.org/10.1007/BF00254534

Download citation

Keywords

  • Carcinoma
  • Primary Tumor
  • Small Intestine
  • Drug Concentration
  • Urinary Excretion